Wu Chun-Wei, Wu Jiunn-Yih, Lee Meng-Tse Gabriel, Lai Chih-Cheng, Wu I-Lin, Tsai Yi-Wen, Chang Shy-Shin, Lee Chien-Chang
Department of Emergency Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan and Chang Gung University College of Medicine, Taoyuan, Taiwan.
Department of Emergency Medicine, National Taiwan University Hospital, Number 7, Chung-Shan South Road, Taipei, 100, Taiwan.
BMC Pulm Med. 2017 May 4;17(1):82. doi: 10.1186/s12890-017-0425-3.
Mycobacterium tuberculosis (TB) is one of the world's most devastating public health threats. Our goal is to evaluate whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) affect the risk of new incident active TB disease.
We conducted a nested case-control analysis by using a 1 million longitudinally followed cohort, from Taiwan's national health insurance research database. Effects of NSAIDs on active TB were estimated by conditional logistic regression and adjusted using a TB-specific disease risk score (DRS). NSAIDs exposures were defined as having a prescription record of NSAIDs ≧ 7 days that ended between 31 and 90 days prior to the index date.
A total of 123,419 users of traditional NSAIDs, 16,392 users of cyclooxygenase-2 selective inhibitor (Coxibs), and 4706 incident cases of active TB were identified. Compared with nonusers, use of traditional NSAIDs was associated with an increased risk of TB in the unadjusted analysis ([RR], 1.39; 95% [CI], 1.24 - 1.57 and DRS adjusted analysis ([ARR], 1.30; 95% [CI], 1.15- 1.47). However, use of Coxibs was not associated with a significant increase in the risk of TB after DRS adjustment ([ARR], 1.23; 95% [CI], 0.89 - 1.70).
In this large population-based study, we found that subjects using traditional NSAIDs were associated with increased risk for active TB. We did not find evidence for a causative mechanism between traditional NSAIDs and TB, and more research is required to verify whether the association between traditional NSAIDs and TB is causal, or simply reflects an increased use of anti-inflammatory drugs in the early phases of TB onset.
结核分枝杆菌是全球最具破坏性的公共卫生威胁之一。我们的目标是评估使用非甾体抗炎药(NSAIDs)是否会影响新发活动性结核病的风险。
我们利用台湾国民健康保险研究数据库中100万例纵向随访队列进行了一项巢式病例对照分析。通过条件逻辑回归估计NSAIDs对活动性结核病的影响,并使用结核病特异性疾病风险评分(DRS)进行调整。NSAIDs暴露定义为在索引日期前31至90天之间结束的NSAIDs处方记录≧7天。
共识别出123419名传统NSAIDs使用者、16392名环氧化酶-2选择性抑制剂(Coxibs)使用者和4706例活动性结核病例。与未使用者相比,在未调整分析中,使用传统NSAIDs与结核病风险增加相关(相对风险[RR],1.39;95%可信区间[CI],1.24 - 1.57),在DRS调整分析中也是如此(归因风险[ARR],1.30;95%CI,1.15 - 1.47)。然而,在DRS调整后,使用Coxibs与结核病风险显著增加无关(ARR,1.23;95%CI,0.89 - 1.70)。
在这项基于人群的大型研究中,我们发现使用传统NSAIDs的受试者患活动性结核病的风险增加。我们没有找到传统NSAIDs与结核病之间因果机制的证据,需要更多研究来验证传统NSAIDs与结核病之间的关联是因果关系,还是仅仅反映了结核病发病早期抗炎药物使用的增加。